Amended and Restated Warrant To Purchase Common StockCorMedix Inc. • September 16th, 2014 • Pharmaceutical preparations • New York
This Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 15 day of September, 2014, and amends and restates the Warrant to Purchase Common Stock issued by the Company on January 8, 2014 (the “Issuance Date”) to ______________________ (the “Holder”) pursuant to that certain Securities Purchase Agreement dated January 7, 2014 (the “Securities Purchase Agreement”). The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant, at any time or times on or after January 8, 2014 (the “Initial Exercisability Date”), but not after 11:59 p.m., New York time, on
CORMEDIX INC. Amended and Restated Warrant To Purchase Common StockCorMedix Inc. • September 16th, 2014 • Pharmaceutical preparations • New York
This Amended and Restated Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) of CorMedix Inc. (the “Company”) is issued this 15 day of September, 2014, and amends and restates the Warrant to Purchase Common Stock issued by the Company on March 10, 2014 (the “Issuance Date”) to ______________________ (the “Holder”) pursuant to that certain Subscription Agreement dated March 4, 2014 (the “Subscription Agreement”). The Company hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Holder or its permitted assigns is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or aft
CONSENT AND EXCHANGE AGREEMENTConsent and Exchange Agreement • September 16th, 2014 • CorMedix Inc. • Pharmaceutical preparations • New York
This Consent and Exchange Agreement (the “Agreement”) is made as of this 15 day of September 2014, by and among CorMedix Inc., a Delaware corporation (the “Company”), and the undersigned holders (the “Holders”) of all of the outstanding warrants to purchase common stock, $0.001 par value, of the Company (the “Common Stock”) issued by the Company on March 10, 2014 (the “March 2014 Warrants”).
CONSENT AND EXCHANGE AGREEMENTConsent and Exchange Agreement • September 16th, 2014 • CorMedix Inc. • Pharmaceutical preparations • New York
This Consent and Exchange Agreement (the “Agreement”) is made as of this 15 day of September 2014, by and among CorMedix Inc., a Delaware corporation (the “Company”), and the undersigned holders (the “Holders”) of (i) all of the outstanding shares (the “Existing Series C-2 Stock”) of the Company’s non-voting convertible Series C-2 preferred stock (the “Series C-2 Preferred Stock”), (ii) all of the outstanding shares (the “Existing Series D Stock”) of the Company’s non-voting convertible Series D preferred stock (the “Series D Preferred Stock”), (iii) all of the outstanding shares (the “Existing Series E Stock”) of the Company’s non-voting convertible Series E preferred stock (the “Series E Preferred Stock”), (iv) all of the outstanding warrants to purchase common stock, $0.001 par value, of the Company (the “Common Stock”) issued by the Company in May 2013 (the “May 2013 Warrants”), and (v) all of the outstanding warrants to purchase common stock of the Company issued by the Company in
